First-line trastuzumab deruxtecan significantly improves progression-free survival in HER2-mutant lung cancer

First-line attraction with trastuzumab deruxtecan (T-DXd) importantly improved progression-free endurance compared with pembrolizumab positive platinum-based chemotherapy successful patients with precocious oregon metastatic HER2-mutant non-small compartment lung crab (NSCLC), according to superior results from the signifier 3 DESTINY-Lung04 proceedings presented astatine the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference connected Lung Cancer (WCLC).